Gilad Oren's Form 4 filing
Aprea Therapeutics, Inc.APRE · filed Mar 14, 2024
- Accession no.
- 0001104659-24-034670
- Filed
- Mar 14, 2024
- Trade date
- Mar 13, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 2 derivative transactions. Open-market purchases total $14.6K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gilad OrenCIK 0001929300 | Director, Officer (President, CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2024 | Common Stock | PPurchaseAcquired | +2,000 | $7.29 | +$14,580 | 324,770 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.
Referenced by the price of 1 transaction in Table II.
- F6
The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.
Referenced by the price of 1 transaction in Table II.